What question did this study set out to answer?

The study aims to confirm the efficacy of lorlatinib in treating ALK-positive metastatic NSCLC in patients who have previously received other ALK inhibitors.

April 10, 2026

Lorlatinib in patients with ALK -positive metastatic NSCLC previously treated with an ALK inhibitor: results from a phase IV study

Key Points

The study aims to confirm the efficacy of lorlatinib in treating ALK-positive metastatic NSCLC in patients who have previously received other ALK inhibitors.
Phase IV open-label study conducted with patients having ALK-positive metastatic NSCLC
Participants had previously been treated with alectinib or ceritinib
Efficacy measures included overall response rate and progression-free survival
85% of patients had received prior treatment with alectinib and 15% with ceritinib
The overall response rate was 42% with a median treatment duration of 9.7 months
Median progression-free survival was 12.2 months for participants

Abstract

AIMS: This post-approval study was conducted to confirm efficacy of lorlatinib in anaplastic lymphoma kinase ( PATIENTS median duration of response was not reached. Median progression-free survival was 12.2 months (95% CI, 6.9-22.1). In patients with central nervous system metastases ( CONCLUSIONS: These phase IV efficacy and safety results remained consistent with the pivotal phase I/II study. Lorlatinib continued to show clinically meaningful benefit in patients with previously treated CLINICAL TRIAL REGISTRATION: clinicaltrials.gov identifier is NCT04362072. What is this article about?Non-small cell lung cancer (NSCLC) that has spread to other parts of the body and has changes in a gene called anaplastic lymphoma kinase

Bookmark

Cite This Study

Bearz et al. (Wed,) studied this question.

synapsesocial.com/papers/69d896a46c1944d70ce083a2 https://doi.org/https://doi.org/10.1080/14796694.2026.2653679

Bookmark